Dr. Melina Reisenberg

Dr. Melina Reisenberg currently serves as the Head of Corporate Strategic Planning at ITM Isotope Technologies Munich SE, a position held since January 2022. Prior to this, Dr. Reisenberg worked as a self-employed biotech consultant from July 2017 to December 2021, and held roles at goetzpartners as an Associate, Fuld + Company as an Analyst, and GlobalData Healthcare as a Business Analyst from 2013 to 2017, focusing on oncology and neurology forecasting. Dr. Reisenberg earned a PhD in Neuroscience from King's College London, where research involved the endocannabinoid system and adult neurogenesis. Additional academic qualifications include an MSc in Molecular Biology and a BSc in Molecular Biology from Westphalia University of Applied Sciences. Early career experience includes laboratory work in a hospital setting and various research positions. Dr. Reisenberg's expertise encompasses project management, research, data analysis, and scientific communication.